ERYTECH Pharma S.A. – NASDAQ:ERYP
ERYTECH Pharma S.A. stock price today
ERYTECH Pharma S.A. stock price monthly change
ERYTECH Pharma S.A. stock price quarterly change
ERYTECH Pharma S.A. stock price yearly change
ERYTECH Pharma S.A. key metrics
Market Cap | 47.38M |
Enterprise value | N/A |
P/E | -82 |
EV/Sales | N/A |
EV/EBITDA | 1.69 |
Price/Sales | N/A |
Price/Book | 0.96 |
PEG ratio | -3.08 |
EPS | 0.01 |
Revenue | N/A |
EBITDA | 4.52M |
Income | 614K |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeERYTECH Pharma S.A. stock price history
ERYTECH Pharma S.A. stock forecast
ERYTECH Pharma S.A. financial statements
| Mar 2022 | 0 | -11.07M | |
|---|---|---|---|
| Jun 2022 | 0 | 10.88M | |
| Sep 2022 | 0 | -5.13M | |
| Dec 2022 | 0 | 5.93M |
| Dec 2021 | 66768000 | 43.92M | 65.78% |
|---|---|---|---|
| Jun 2022 | 65987000 | 43.55M | 66% |
| Dec 2022 | 45811000 | 22.32M | 48.73% |
| Mar 2023 | 0 | 0 |
| Dec 2019 | -6.63M | -515K | -341K |
|---|---|---|---|
| Jun 2020 | 0 | -437K | 1.12M |
| Sep 2020 | 0 | 0 | 0 |
| Dec 2020 | 0 | 0 | 0 |
ERYTECH Pharma S.A. alternative data
| Aug 2023 | 49 |
|---|---|
| Sep 2023 | 49 |
| Oct 2023 | 49 |
| Nov 2023 | 49 |
| Dec 2023 | 49 |
| Jan 2024 | 49 |
| Feb 2024 | 49 |
| Mar 2024 | 49 |
| Apr 2024 | 49 |
| May 2024 | 49 |
| Jun 2024 | 49 |
| Jul 2024 | 49 |
ERYTECH Pharma S.A. other data
| Quarter | Transcript |
|---|---|
| Q1 2023 13 May 2023 | Q1 2023 Earnings Call Transcript |
| Q3 2022 22 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 13 Sep 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 13 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Gil Beyen BVBA (1962) Chief Executive Officer & Director | $668,340 |
Mr. Eric Soyer Ph.D. (1966) Chief Financial Officer, Chief Operating Officer & Deputy GM | $411,200 |
Dr. JĂ©rĂ´me Bailly Pharm.D. (1979) Deputy GM of Operations, Chief Quality Officer & Qualified Person | $258,700 |
-
What's the price of ERYTECH Pharma S.A. stock today?
One share of ERYTECH Pharma S.A. stock can currently be purchased for approximately $0.78.
-
When is ERYTECH Pharma S.A.'s next earnings date?
Unfortunately, ERYTECH Pharma S.A.'s (ERYP) next earnings date is currently unknown.
-
Does ERYTECH Pharma S.A. pay dividends?
No, ERYTECH Pharma S.A. does not pay dividends.
-
How much money does ERYTECH Pharma S.A. make?
ERYTECH Pharma S.A. has a market capitalization of 47.38M.
-
What is ERYTECH Pharma S.A.'s stock symbol?
ERYTECH Pharma S.A. is traded on the NASDAQ under the ticker symbol "ERYP".
-
What is ERYTECH Pharma S.A.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ERYTECH Pharma S.A.?
Shares of ERYTECH Pharma S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ERYTECH Pharma S.A.'s key executives?
ERYTECH Pharma S.A.'s management team includes the following people:
- Mr. Gil Beyen BVBA Chief Executive Officer & Director(age: 63, pay: $668,340)
- Mr. Eric Soyer Ph.D. Chief Financial Officer, Chief Operating Officer & Deputy GM(age: 59, pay: $411,200)
- Dr. JĂ©rĂ´me Bailly Pharm.D. Deputy GM of Operations, Chief Quality Officer & Qualified Person(age: 46, pay: $258,700)
-
How many employees does ERYTECH Pharma S.A. have?
As Jul 2024, ERYTECH Pharma S.A. employs 49 workers.
-
When ERYTECH Pharma S.A. went public?
ERYTECH Pharma S.A. is publicly traded company for more then 9 years since IPO on 5 Jul 2016.
-
What is ERYTECH Pharma S.A.'s official website?
The official website for ERYTECH Pharma S.A. is erytech.com.
-
How can i contact ERYTECH Pharma S.A.?
ERYTECH Pharma S.A. can be reached via phone at +33 4 78 74 44 38.
ERYTECH Pharma S.A. company profile:
ERYTECH Pharma S.A.
erytech.comNASDAQ
49
Biotechnology
Healthcare
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Lyon, 69008
CIK: 0001624422
ISIN: US29604W1080
CUSIP: 29604W108
